BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 27755239)

  • 1. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
    Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e19-e26. PubMed ID: 27755239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
    Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S19-26. PubMed ID: 27183521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors.
    Tocchetti CG; Gallucci G; Coppola C; Piscopo G; Cipresso C; Maurea C; Giudice A; Iaffaioli RV; Arra C; Maurea N
    Eur J Heart Fail; 2013 May; 15(5):482-9. PubMed ID: 23325019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
    Maurea N; Spallarossa P; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e93-e104. PubMed ID: 27755247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.
    Dokmanovic M; King KE; Mohan N; Endo Y; Wu WJ
    Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):755-766. PubMed ID: 28571477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
    Schneider JW; Chang AY; Rocco TP
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
    Riccio G; Coppola C; Piscopo G; Capasso I; Maurea C; Esposito E; De Lorenzo C; Maurea N
    Hum Vaccin Immunother; 2016 May; 12(5):1124-31. PubMed ID: 26836985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy.
    De Keulenaer GW; Doggen K; Lemmens K
    Circ Res; 2010 Jan; 106(1):35-46. PubMed ID: 20056944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
    Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
    Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.
    Sundararajan S; Kumar A; Poongkunran M; Kannan A; Vogelzang NJ
    Future Oncol; 2016; 12(8):1067-80. PubMed ID: 26901457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity of Targeted Cancer Drugs: Concerns, "The Cart Before the Horse," and Lessons from Trastuzumab.
    Menna P; Minotti G; Salvatorelli E
    Curr Cardiol Rep; 2019 Mar; 21(5):33. PubMed ID: 30887161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
    Yu AF; Yadav NU; Eaton AA; Lung BY; Thaler HT; Liu JE; Hudis CA; Dang CT; Steingart RM
    Oncologist; 2015 Oct; 20(10):1105-10. PubMed ID: 26240135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
    Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
    JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors.
    Chen YC; Chung CC; Lin YK; Chen YJ
    Ann Med; 2018 Feb; 50(1):46-56. PubMed ID: 28929822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
    Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
    Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.
    Schneider JW; Chang AY; Garratt A
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):22-8. PubMed ID: 12138394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity of systemic agents used in breast cancer.
    Ades F; Zardavas D; Pinto AC; Criscitiello C; Aftimos P; de Azambuja E
    Breast; 2014 Aug; 23(4):317-28. PubMed ID: 24794210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs.
    Mercurio V; Pirozzi F; Lazzarini E; Marone G; Rizzo P; Agnetti G; Tocchetti CG; Ghigo A; Ameri P
    J Card Fail; 2016 Jun; 22(6):449-58. PubMed ID: 27103426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
    Telli ML; Hunt SA; Carlson RW; Guardino AE
    J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardio-oncology Part I: chemotherapy and cardiovascular toxicity.
    O'Hare M; Sharma A; Murphy K; Mookadam F; Lee H
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):511-8. PubMed ID: 25843285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.